Demolition of 'deteriorating' seaside café approved
Harbourside Holidays intends to replace the three-storey Waterfront Bar at 39 Sandside, Scarborough, with a four-storey structure, including a café on the ground floor, with three holiday flats on the upper floors.
Planning officers acknowledged the demolition would see the loss of a "traditional structure", but said alterations to the original building meant it no longer contributed "to the character and appearance of the conservation area".
The application was approved subject to conditions, including limiting the hours of the café from 09:00 to 23:00, Monday to Friday.
One resident lodged an objection to the scheme, citing concerns about "further erosion of the historic scale of this part of Scarborough".
They said the plan would not "respect the domestic character of Quay Street", adding, "Scarborough is also being overprovided with holiday lets".
According to the Local Democracy Reporting Service a letter of support for the plan was also submitted, stating the applicant had undertaken other work in the area which, if matched by the new development, would "enhance the area".
A report noted that the offer of an additional holiday accommodation unit respected "the existing character of the area".
Officers concluded: "The building is beginning to deteriorate and may have a harmful impact on the street scene in the near future if left unaltered."
Listen to highlights from North Yorkshire on BBC Sounds, catch up with the latest episode of Look North.
More stories like this
Gas drill plans opposed by town council and MP
Related internet links
Local Democracy Reporting Service
North Yorkshire Council
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
Prime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
CAMBRIDGE, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the closing of its underwritten public offering of 43,700,000 shares of its common stock, which includes the full exercise of the underwriters' option to purchase 5,700,000 additional shares of its common stock, at a public offering price of $3.30 per share. The underwriters did not receive any discounts or commissions with respect to an aggregate of 1,818,181 shares of common stock sold to the Cystic Fibrosis Foundation. All of the shares of common stock in the offering were sold by Prime Medicine. The gross proceeds to Prime Medicine from the offering, before deducting underwriting discounts and commissions and offering expenses, were approximately $144.2 million. TD Cowen and BMO Capital Markets acted as joint book-running managers for the offering. The shares of common stock were offered by Prime Medicine pursuant to an effective shelf registration statement on Form S-3 that was previously filed with the U.S. Securities and Exchange Commission (SEC) on November 3, 2023 and declared effective by the SEC on November 13, 2023 (File No. 333-275321). The offering was made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A final prospectus supplement relating to and describing the terms of the offering was filed with the SEC and is available on the SEC's website at Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained from TD Securities (USA) LLC, 1 Vanderbilt Avenue, New York, New York 10017, by telephone at (855) 495-9846, or by email at or BMO Capital Markets Corp., Attention: Equity Syndicate Department, 151 West 42nd Street, 32nd Floor, New York, New York 10036, by email at bmoprospectus@ This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. About Prime Medicine Prime Medicine is a leading biotechnology company dedicated to creating and delivering the next generation of gene editing therapies to patients. The Company is deploying its proprietary Prime Editing platform, a versatile, precise and efficient gene editing technology, to develop a new class of differentiated one-time curative genetic therapies. Prime Editors are designed to make only the right edit at the right position within a gene while minimizing unwanted DNA modifications. Prime Medicine is currently progressing a diversified portfolio of investigational therapeutic programs organized around our core areas of focus: liver, lung, and immunology and oncology. Across each core area, Prime Medicine is focused initially on a set of high value programs, each targeting a disease with well-understood biology and a clearly defined clinical development and regulatory path. Investor and Media ContactsGregory DearbornPrime Medicine857-209-0696gdearborn@ Hannah DeresiewiczPrecision
Yahoo
19 minutes ago
- Yahoo
Moderna Cuts Forecast, Stock Wobbles Despite Beat
Moderna's (NASDAQ:MRNA) quarter was okay on the numbers, but the stock slid because the company pulled back its full-year revenue outlook after delaying some U.K. vaccine shipments into early 2026. Q2 revenue was $142Million, down 41% from a year ago, with COVID shot sales at $114Million and its RSV vaccine barely registering. That pushed the 2025 revenue range to $1.5Billion$2.2Billion, about $300Million less than before. Warning! GuruFocus has detected 2 Warning Sign with MRNA. The good part is they've been cutting costs aggressively. OpEx is now guided to $5.9Billion$6.1Billion roughly $400Million lighter than prior expectationsand that helped trim the loss to about $800Million. Moderna still has a strong cash cushion: $7.5Billion at the end of June and roughly $6Billion expected at year-end, so the balance sheet isn't stressed. The delayed shipments rattled sentiment, but the company isn't burning cash. Now it comes down to executionU.K. deliveries must land as rescheduled and new revenue drivers need to show up before investors lose patience. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
19 minutes ago
- Yahoo
Liverpool ENTER midfielder transfer talks
Liverpool have entered talks over a potential £15m transfer. As much as Richard Hughes will be honing on on new arrivals at the moment with the focus very much on Alexander Isak, and bringing in a new centre-back, there are still going to be some departures at the club as well. 🔴 Shop the LFC 2025/26 adidas home range from 9am TODAY Shop the LFC Store LFC x adidas Shop the away range TODAY LFC x adidas Shop the home range today! LFC x adidas Shop the goalkeeper range today LFC x adidas Shop the new adidas range today! There remains question marks over the future of Harvey Elliott, Federico Chiesa and Kostas Tsimikas. Meanwhile, at this point who knows what fate Darwin Nunez holds. These transfer deals are going to be crucial for Liverpool in order to balance the books. The Reds have spent a lot of money this summer but they also stand to recoup the vast majority of what they have spent through sales. Elliott in particular is going to command a significant fee. Meanwhile, Nunez, if Liverpool can find the right suitor, won't be leaving on the cheap either. And the Reds have also entered talks to complete a deal that would count as 'pure profit' when it comes to the Premier League's Profit and Sustainability Rules (PSR). 🔴 Shop the LFC 2025/26 adidas away range from 9am TODAY According to Sky Sports News, Liverpool are in talks with Lyon to sell Tyler Morton for what is expected to be a £15m transfer. Morton is an academy graduate, which means Liverpool could count the entire sale as a profit, considering he has been at the club from a young age. The 22-year-old has been on several loan spells over the course of his career and of course caught the eye in the Reds' first team as well. His best performance came against AC Milan in the Champions League at the San Siro in a game where Morton really emerged as a top-prospect. Since then, he has always stood-out for his excellent technical ability and his reading of the game. The only obstacle in his way in terms of making more regular first team minutes has been the level of players ahead of him in the pecking order. Right now Morton will know he is not guaranteed regular playing time but at his age he needs to be playing week in, week out in order to develop. Another loan to the Championship is probably not the right move for him either, having been at Blackburn Rovers and Hull City. This move to Lyon could be an excellent one. He'd be playing in a top five European league, at one of the best teams in that league. On top of that, Morton will be able to play in Europe as well, with Lyon having qualified for the Europa League. Another interesting caveat in these talks is that Liverpool are known for their admiration of Malick Fofana. So, perhaps letting Morton go to Lyon could open up a level of communication between the two sides that may ultimately see the French team return the favour for Fofana. It's definitely something to keep an eye on.
